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Abstract 
Introduction: In this regard, the study of pleiotropic hepatoprotective properties of the 
agonist of peripheral imidazoline receptors C7070 seems interesting from an applied 
point of view. 
Materials and Methods: Models of a skin flap on a feeding leg, ischemia-reperfusion 
of the liver and rat heart isolated from Langendorff (ischemia-reperfusion and 
doxorubicin cardiomyopathy) were used.  
Results and Discussion: The I2 agonist C7070 at a dose of 10 mg/kg 4.5-fold prevents 
the increase in ALT and AST (332.56 ± 22.05/825.49 ± 22.46 ALT/AST 526.90 ± 
17.97/1045.16 ± 80.02 units/l in control) and 2.5 times reduces the areas of ischmeic 
damage and necrosis (0.058 ± 0.029/0.046 ± 0.013 mm2) in the modeling of 15-minute 
ischemia liver. Moxonidine and metformin had a hepatoprotective effect: 44.99 and 
36.88 for moxonidine (ALT and AST) and 34.20 / 21.02 for metformin (ALT / AST). 
The coefficients of histological hepatoprotective activity: 72.33 and 38.96 (moxonidine 
and metformin). 
C7070 (10.0 mg/kg) has a pronounced dermatoprotective activity and prevents the 
formation of necrosis on days 3 and 7 of the pathology by 40%. The dermatoprotective 
activity of metformin (50 mg/kg) from 3 to 10 days decreases from 81% to 92%. The 
dermatoprotective activity of moxonidine (1 μg/kg) was maximal on the 7th day and was 
76%. 
In the isolated rat heart, the C7070 showed a protective effect in ischemia-reperfusion 
and on the model of doxorubicin cardiomyopathy. The STTi index: 8.3, 1.5; 7.9 and 7.8 
U. in control, C7070, moxonidine and metformin. 
Keywords: С7070, metformin, moxonidine, ischemia, reperfusion, liver, skin flap, 
isolated heart, according to Langendorf.  
 
Introduction 
Ischemia is a trigger and a pathogenesis 
stage simulteniously [1]. 
Diabetes mellitus and a metabolic 
syndrome lead to fat hepatic dysthrophy 
transferring into the necrosis of hepar [2]. 
A drug therapy of diabetes mellitus and 
metabolic syndrome have neither 
hepatoprotective effects [3]. 
In this case, a study of additional 
pharmacological correction during the 
biguanide therapy looks very interesting. 
Imidozoline receptors are localized in CNS 
(in the reticular formation cores, rostral 
ventrolateral area of oblong brain) – type I. 
Another type of imidazoline receptors – type II – 
able to be finded on the peripheral tissues 
(hepar, kidneys, pancreas) [4]. The last one was 
also founded based in mitochondrial 
membranes. One more type of imidazoline 
receptors was described as receptors in 
sympatic nerve endings. The activation of these 
receptors decreases the noradrenaline 
production [5]. I1−receptors was also detected 
on the platelet‘s membranes. 
 
Rus. 
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Rilmenidine and moxonidine are high 
selected agonists of I1-receptors. Their affinity 
to the I1-receptors more than to the α2-
adrenoreceptors. Both of them has pronounced 
hypotesive effect. It should be considered as a 
sympatolitic activity of the I1-agonists [6]. 
Imidozoline receptors were detected in 
smooth muscles of airways in the experiments 
on the dogs [7]. 
Imidazoline receptors agonists have same 
pharmacokinetic parameters. It was noticed in 
number of studies, that their effect to the 
imidazoline receptors continuing the whole day, 
despite their short elimination period. Most 
numbers of scintiests consider this property in 
connection with accumulation of these drugs in 
brain and other fat-containing tissues [8, 9, 10, 
11]. 
Intolerance to glucose, overweight, 
dyslipiaemia and arterial hypertension are 
syndicated to the ―metabolic syndrome‖ [12]. 
Probably, hyperinsulinaemia is able to be 
related to the arterial hypertencion 
development. Insuline increases sympatic 
nervous system activity. This leads to the 
increasing of cardiac output and periferial 
vascular resistence [13, 14]. Agonists of central 
imidazoline receptors (I1) have a sympatolitic 
effect [15, 16]. Agonists of peripheral (I2) 
imidazoline receptors decreases the tissue‘s 
insuline resistence, decreasing the level of 
insulin [16]. 
The studies of central imidazoline 
receptors agonists are more common, than the 
peripheral one [17]. 
For example, placebo-controlled study by 
Haenni А., (1999) [16] in 72 patients with AH 
and overweight moxonidine 8-week therapy 
leaded to the reliable insulin sensitivity. This 
effect was detected in glucose intolerance 
group only. The group of patients without 
glucose intolerance the modification of insulin 
sensitivity was not detected. 
The basic role in pathogenesis of diabetes 
mellitus (II type) owned to the two independent 
pathophysiologycal processes: the resistance to 
the insulin and decreasing of its secretion by β-
cells of pancreas [18]. The insulin resistance 
plays important role in metabolic syndrome 
development. Also, the insulin resistance is 
accompanied by hyperinsulinaemia – 
independent factor of heart ischemic disease 
evolution [19]. 
Pharmacological activity of metfrormin 
has not limited by positive influence to the 
carbohydrate metabolism. 
Around at 2/3 patients with 
hyperlypoproteinaemia IIB and IV types without 
diabetes metformin decreases triglyceride level 
over 30%; decreasing of hypercholesterinaemia is 
less pronounced [9, 12]. 
Modern hypoglycemic drugs are able to 
exert positive pleotropic effects to pancreas. 
But their activity is not enough to prevent 
diabetes‘s complications. 
In the view of foregoing, the vantage of 
peripheral imidazoline receptors agonists, as a 
medicines affecting early diabetic patient‘s 
survival, becomes obvious. 
The purpose of this study was detection of 
vascular complication‘s protection of diabetic 
patients. 
Materials and Methods 
White Wistar rats were chosen for this 
study as standard animals for specific activity 
studies according to National pre-clinic studies 
manual (2012). There were used 180 rats both 
sexes. 
Doses of medicines 
Every used dosage was derived with help 
of the interspecific recount of doses according 
to human minimal therapeutic doses. 
The minimal therapeutic dose for C7070 
was detected as 100 mg for adult human. Using 
the formula, the dose 10 mg/kg for rats was 
obtained. 
Metformin has 500 mg as a minimal 
therapeutic dose for human. According to 
formula, 50 mg/kg was selected as rat dose. 
For moxonidine were obtained the rat dose 
20 µg/kg (minimal therapeutic dose for human 
– 0.2 mg) 
Data for minimal therapeutic doses were 
detected in instructions for use of the 
medication. 
During the using of langenorff models the 
equivalent doses of medicines were added into 
the prfusate. 
Pharmacological methods. 
For the study of ischemised skin flap 
survival 40 both sex rats were used. The 
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animals were divided into the 4 groups (n=10): 
contoll group; metformin (50 mg/kg) group; 
moxonidine (20 µg/kg) group; C7070  
(10 mg/kg) group. 
Method of E.V. Kizhaev (1986) in P.A. 
Galenco-Yaroshevski was used in this model [20]. 
The first one was the formation of skin flap 
on the anterior abdominal wall. Then, studying 
medicines were administrated into the animals 
per os. Calculation of necrosis area at 3
rd
, 7
th
 
and 10
th
 days with help of computer modeling 
was the third stage of this experiment. 
The study of hepatotropic activity of 
these medicines was carried out using the  
D.A. Lopatin [21] method. 
60 both sex rats were operated in this model. 
The animals were divided into the 6 groups 
(n=10): intact groups; pseudooperated animals 
(without vascular ligation); control group, 
metformin (50 mg/kg) group; moxonidine (20 
µg/kg) group; C7070 (10 mg/kg) group. 
All animals survived this experiment. 
ALT and AST were chosen as biochemical 
markers of hepatic function. The structural 
changes evaluated with the help of hepatic 
histology. 
The study of anti-ischemic cardio 
protective activity was made using isolated 
heart by Langendorff [22, 23, 24, 25, 26]. The 
animals were divided into the 4 groups (n=10): 
contoll group; metformin (50 mg/kg) group; 
moxonidine (20 µg/kg) group; C7070  
(10 mg/kg) group. 
The next functional indexes for heart work 
were chosen: left ventricular pressure (LVP), 
heartbeat (HB), the power of heart systole and 
diastole (+dp/dt and – dp/dt). All the indexes 
were registered by Biopac Inc. system 
hardware using the ACQ Knowledge software. 
Parameters were detecting during the whole 
experiment [27, 28, 29, 30, 31]. 
The model of doxorubicine 
cardiomyopathy was designed and patented 
by group of scientists in Center of Pre-Clinic 
and Clinic Trials of Belgorod State National 
Research University (including the author of 
this article). 
50 both sex animals were divided into the 
5 groups (n=10): intact groups; control group 
(doxorubixine 20 mg/kg); doxorubixine  
(20 mg/kg) + metformin (50 mg/kg) group; 
doxorubixine (20 mg/kg) + moxonidine  
(20 µg/kg) group; doxorubixine (20 mg/kg) + 
C7070 (10 mg/kg) group. 
In 3 days before the modeling all 
experimental animals started administration of 
studying medicines per os. After an hour 
doxorubicine (20 mg/kg) was administrated 
into the rats intraperitoneal. 
 
Results and Discussion 
1. The influence of peripheral 
imidazoline receptors agonists at skin flap 
survival. 
Intragastric administration of studying 
drugs leads to the increasing of skin flap 
survival. The agonist of peripheral imidazoline 
receptors (C7070) had the biggest anti-
ischemic activity (tab. 1). 
Table 1 
THE influence of C7070 (10 mg/kg), moxonidine (20 µg/kg) and metformin (50 mg/kg)  
at the degree of skin flap necrosis at rats. (%) (M±m) 
 
Drugs and doses 
Skin flap necrosis’s degree, % 
3
rd
 day 7
th
 day 10
th
 day 
Control 30.9±2.8 65.7±2.6 84.5±3.2 
С7070 (10 mg/kg) 21.5±3.1* 41.4±3.2* 68.4±2.7* 
Moxonidine (20 µg/kg) 24.8±2.9* 50.5±3.0* 77.0±2.7* 
Metformin (50 mg/kg) 25.4±2.4* 59.2±2.2* 78.3±2.9* 
Note: *–p>0.05 in comparison with control group 
 
Agonist of peripheral imidazoline 
receptors C7070 has more powerful 
dermatoprotective activity in comparing with 
moxonidine and metformin. 
 Dovgan A.P. Ligand of peripheral imidazoline receptors based on amides of heterocyclic acids 
C7070: effect on ishemized tissues. Research Results in Pharmacology. 2017;3(4):78-88. 
81 
 
December. 2017. 3(4). Research Results in Pharmacology rrpharmacology.ru 
This difference is able to be controlled by 
influence of C7070 at the vascular tonus. From 
the other side, we can expect this difference 
due to mitochondrial protection of C7070. It 
leads to maintaining of work capacity of skin 
cells. 
But, during the time, the difference 
between studing drugs‘ effects increasing from 
5% at 3
rd
 day to 10% at 10
th
 day. 
2. The influence of peripheral 
imidazoline receptors’ agonist at hepar 
damage due to ischemia-reperfusion. 
All animals survived the experiment. 
The levels of AST and ALT were 
measured in blood of experimental animals 
after their euthanasia (3 days after modeling). 
The next numbers were detected in 
biochemical blood analysis (tab. 2).  
So, laporotomy has no significant impact 
to the ALT and AST levels. 15 minutes of 
hepatic ischemia and following reperfusion 
reliably increase the ALN and AST levels. 
Using studying drugs decrease hepatic 
ferments‘ level. But even peripheral 
imidazoline receptors agonist C7070 was not 
able to return ferment level back to the control 
group numbers. 
Despite this, C7070 had the highest anti-
ischemic activity among all studied medicines 
in this experiment. 
Hepatic ferments‘ levels are not enough to 
evaluate anti-ischemic activity of these drugs. 
That‘s why the rat liver was excise 3 days after 
modeling to describe its histological image. 
Ischemic damage area and ischemic 
necrosis area was chosen as histology markers 
of structural damage (tab. 3). 
Table 2  
The influence of C7070 (10 mg/kg), moxonidine (20 µg/kg) and metformin (50 mg/kg)  
at the mean values of ALT and AST in blood of experimental animals (U/ml) (M±m) 
 
Animal group ALT, U/ml AST, U/ml 
Intact 102.8±8.8 284.1±19.3 
Pseudo-operated 110.2±21.9* 289.8±16.2* 
Control 526.9±17.9** 1045.1±80.0** 
С7070 (10 mg/kg) 143.2±16.91 395.8±33.31 
Moxonidine (20 µg/kg) 289.8±15.21 687.7±28.31 
Metformine (50 mg/kg) 332.5±22.01 825.4±22.41 
Note: *–p>0,05 in comparison with intact group; **– p<0,05 in comparison with psedo-operared 
group; 1 – p<0,05 05 in comparison with control group. 
Table 3  
The influence of C7070 (10 mg/kg), moxonidine (20 µg/kg) and metformine (50 mg/kg)  
to the hepatic damage area, mm
2
 (M±m) 
 
Animal group Iscemic damage area, mm
2 
Iscemic necrosis area, mm
2
 
Intact n/a n/a 
Pseudo-operated n/a n/a 
Control 0.387±0.014 0.207±0.021 
С7070 (10 mg/kg) 0.058±0.029* 0.046±0.013* 
Moxonidine (20 µg/kg) 0.090±0.025* 0.075±0.015* 
Metformin (50 mg/kg) 0.238±0.052* 0.125±0.020* 
Note: *–p>0.05 in comparison with control group 
Histological examination did not detected 
significant sings of ischemic damage or 
necrosis in intact or pseudo-operated animal 
group. 
Thus, peripheral imidaazolinee receptors‘ 
agonist C7070 has the highest hepatoprotective 
properties in frames of this study. 
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3. The influence of peripheral 
imidazoline receptors’ agonist C7070 to the 
functional ischemic isolated heart damage. 
(by Langendorff) 
It was detected, that decreasing of 
perfusion in 10 times (ischemic hypoperfusion) 
all selected parameters (HB, LVP, +dP/dtmax, -
dP/dtmax) were significant decreased by 5
th
 
minute. They didn‘t back to the normal level by 
20
th
 minute.  
During the reperfusion these parameters 
were less than start level by 5
th
 minute of 
experiment. The same image we had by 20
th
 
minute of reperfusion, when most of 
parameters had less than half of start level (tab. 
4). Besides, the recovery of perfusion volume 
(reperfusion) leaded to the reperfusion 
arrhythmias (30% fibrillations in cases). 
 
Thus, moxonidine and metformin haven‘t 
significant influence to the heart muscle 
working. The same time, peripheral 
imidazoline receptors‘ agonist C7070 allowed 
cardiomyocytes to contract with the almost 
same power and frequency as heart without 
ischemia. 
Metformin and moxonidine have a central 
and common activity to the whole organism. 
Peripheral imidazoline receptors‘ agonist 
C7070 has the action realized on the cells‘ 
level. That‘s why this medicine is able to work 
in isolated heart. Transmembrane ion current 
control and ATP‘ase channels normalization 
allows C7070 significant decrease the heart 
ischemic damage. 
In this connection, the question about 
decreasing of cardiotoxic drugs effects by 
C7070 is very interesting. 
The most socially significant of them are 
antineoblastome antracycline drugs [32, 33]. 
Doxorubicine cardiomyopathy model 
has been used in this experiment. 
This model uses the comparison of control 
animal group (doxorubicine 20 mg/kg 2 days 
before modeling) with intact group. And 
comparison of experiment groups with control. 
The coefficient of AUC in time of 15‖ 
stimulating count was derived and patented 
specially for this model. 
The stimulation of dilated by doxorubicine 
heart with help of electric stimulator leads to 
diastolic dysfunction. It express in increasing of 
minimal left ventrical pressure in time of 
electric stimulation. So, it leads to the 
increasing AUC level. The coefficient STTi 
shows the degree of diastolic dysfunction. Its 
meaning inversely to the cardioprotective 
activity of the drug. 
The results of experiment are able in fig. 1. 
 
 
Fig. 1. The coefficient STTi for C7070 (10 mg/kg), moxonidine (20 µg/kg)  
and metformine (50 mg/kg) in modeling of doxorubicine (20 mg/kg) cardiomyopathy 
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Table 4  
The influence of C7070 (10 mg/kg), moxonidine (20 µg/kg) and metformine (50 mg/kg) to the heart function measures (M±m, n=10) 
Animal group Control Moxonidine, 20 µg/kg 
Metformin, 50 
mg/kg 
С7070, 10 mg/kg 
Start level 
LVP 129.0±2.4 127.4±3.7 130.1±1.1 125.1±1.1 
+dp/dt 2728.0±38.4 2694.3±46.1 2697.7±39.4 2799.3±20.0 
-dp/dt 1346.4±41.2 1342.1±25.0 1331.1±36.1 1235±31.2 
HB 168.1±22.4 179.2±11.8 165.4±18.9 160.1±15.3 
Hypo perfusion time 
5‘ 
LVP 50.75±7.6 48.47±4.1 50.81±5.2 65.84±3.4* 
+dp/dt 1114.0±12.4 1181.2±21.2 1102.5±15.8 1276.4±11.7* 
-dp/dt 613.1±11.2 625±1.2 617±7.6 656±4.1* 
HB 76.6±2.4 78.1±4.3 74.1±3.7 85.6±1.1* 
20‘ 
LVP 28.2±1.4 23.48±4.2 26.94±3.1 39.63±2.3* 
+dp/dt 448.8±12.4 441.6±22.1 442.4±15.8 629.8±14.4* 
-dp/dt 306.7±9.8 307.8±6.7 309.5±7.1 378.4±11.2* 
HB 213.1±7.2 211.8±6.4 215.6±8.2 280.4±4.5* 
Reperfusion time 
5‘ 
LVP 101.9±2.5 115.9±4.9 128.7±7.1* 126.8±5.8* 
+dp/dt 2079.4±84.5 1991.5±86.1 1987±74.9 2564±81.2* 
-dp/dt 1137.1±25.8 1195.0±29.7 989±15.3* 1215±20.8* 
HB 191.7±9.8 195.8±8.3 171.5±7.4* 161.9±9.1* 
20‘ 
LVP 101.3±8.6 115.4±7.5 125.8±5.1* 129.5±4.3* 
+dp/dt 2121.1±30.8 2095.4±35.6 2184.6±29.3 2859±38.5* 
-dp/dt 1137.0±25.4 1184.4±21.3 1121.1±36.4 1279±30.1* 
HB 181.8±10.8 185.4±9.6 169.5±11.2 160.2±3.6* 
Note: LVP – left ventrical pressuare, ―+dp/dt‖ – heart systolic power; ―-dp/dt‖ – heart diastolic power; HB – heartbeat. *–p>0,05 in comparison with 
control group 
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Conclusion 
Thus, peripheral imidazoline receptors‘ 
agonist C7070 had the highest anti-ischemic 
properties among all medicines included in this 
study. 
All differences are able to be explaned by 
their mechanisms of action. 
Metformin‘s mechanism of action based on 
decreasing of gluconeogenesis. Also, 
metformine plays one of the main roles in 
insulin peripheral effects increasing, anaerobe 
glucose metabolic way increasing, lipless 
decreasing.  
In number in vivo and in vitro studies the 
metformin influence to the cell AMP-kinase 
was detected. This enzyme plays a role in 
glucose transport through the membranes with 
help of GLUT4 enzyme. Besides, metformin 
has showed the ability to cell membrane 
rigidity decreasing. It is one of the frequent 
condition able to lead to the diabetes‘s 
complications [20]. 
Metformin actives AMP-activated 
proteinkinase (AMPK) – hepatic enzyme of 
insulin signalization. AMPK also playing a role 
in common energy balance and glucose and 
lipid metabolism. AMPK activation is 
necessary stage for metformin inhibition effect 
to hepatic gluconeogenesis [14]. 
Resuming the foregoing, anti-ischemic 
metformin action based on energy reserves 
cumulating and decreasing of current nutrial 
reserves spending. 
Moxonidine is a central imidazoline 
receptors‘ agonist. It takes a part in 
redistribution of hepatic bloodstream through 
the collateral vessels from a. gastrica sinistra. 
They were free from flow reducing. Also, 
moxonidine‘s anti-ischemic activity is able to 
base on vessels‘ opening in reperfusion 
moment [35]. 
There were enough number of pre-clinic 
and clinic trials of imidazoline receptors 
agonists. 
For example, Mukaddam-Daher in his trial 
detected the increasing of diuresis, Na and K 
excretion at rats in moxonidine group. The 
effect was blocked by efaroxan and decreased 
by α-adrenoblocker himbine [11].  
Central I1-receptors of hypothalamic zone 
include in glycemia level control. It was 
showed in experiment with selective I1 agonist 
– agmantin – reduce of glucose blood level. 
The same action has a moxonidine too. 
Besides, imidazoline receptors are able to 
locate in pancreas and control the insulin 
secretion [35]. 
The using of moxonidine at Zucker rats 
leaded to hypothalamic neuropeptid Y level 
decreasing. It is able to be one of the weight-
reducing mechanisms of this drug [15]. 
Probably, some part of these actions realize 
through the α2-adrenoreceptors. The peripheral 
actions of these drugs are able to lead these 
changes too. 
Peripheral imidazoline receptors‘ agonist 
C7070 realize its action through the 
mitochondrial protection. The influence to the 
ATP-channels of external and internal 
mitochondria membranes. Slowing and 
blocking of avalanche current of iron ions leads 
to the oxidative stress decreasing [. 
Imidazoline receptors activation leads to 
the arachnid acid synthesis increasing and 
Na
+
/H
+
 ion change inhibition [17].  
Scientists from Kharkov paid their 
attention to the peripheral imidazoline 
receptors‘ agonists ability to glycemia control. 
According to their studies, anti-diabetic effects 
of these drugs not less than metformin. But, 
C7070 has more favorable toxic profile in 
comparison with biguanides [39]. Besides, 
imidazoline receptors‘ agonists don‘t lead to 
the hypoproteinaemia and hyperlactacidaemia 
progression [40].  
Modern anti-diabetic drugs can lead some 
pleiotropic effects to the pancreas. But their 
activity is not enough to prevent the 
complications. 
So, imidazoline receptors‘ agonists 
advantage as drugs with vascular prevent 
properties becomes obvious. 
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Resuming the foregoing, it is able to 
combine all mechanisms of action into one 
scheme (fig. 2). 
 
Fig. 2. The differences between C7070 and moxonidine mechanisms of action 
 
Findings 
Peripheral imidazoline receptors‘ agonist 
C7070 (10 mg/kg) has pronounced 
dermatoprotective activity and prevents the 
skin flap necrosis progression by 3
rd
 and 7
th
 day 
to 40%. 
Peripheral imidazoline receptors‘ agonist 
C7070 (10 mg/kg) shows 4.5 times less 
increasing of ALT and AST (332.56±22.05/ 
825.49±22.46 U/ml ALT/AST in C7070 group 
versus 526.90±17.97/1045.16±80.02 U/ml in 
control group) and decreases in 2.5 times 
ischemic damage and ischemic necrosis area 
(0.058±0.029 и 0.046±0.013 mm2 respectively) 
in modeling of 15-minute hepatic ischemia. 
Dermatoprotective activity of metformin 
(50 mg/kg) decreases from 81% at 3
rd
 day to 
92% at 10
th
 day. 
Dermatoprotective activity of moxonidine 
(20 µg/kg) was maximal by 7th day – 76%.  
Moxonidine and metformine had a 
hepatoprotective activities too.  
Metformin decreases the level of 
ALT/AST to 332.5±22.0/825.4±22.4 U/ml and 
ischemic damage/necrosis area to 
0.238±0.052/0.125±0.020 mm2. 
Moxonidin parameters were: 
289.8±15.2/687.7±28.3 U/ml for AST/ALT and 
0.090±0.025/0.075±0.015 mm2 for ischemic 
damage/necrosis areas respectively. 
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